Descárgate aquí la Guía Dislipemias 2016

Publicaciones Similares
Evolocumab and Clinical Outcomes in Patients with Card. Disease
Descargue el artículo completo ABSTRACT BACKGROUND Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin–kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60%. Whether it prevents cardiovascular events is uncertain. METHODS We conducted a randomized, double-blind, placebo-controlled trial involving 27,564 patients with atherosclerotic cardiovascular disease and LDL cholesterol levels…
Actualización del algoritmo de hiperglucemia 2017
La diabetes mellitus tipo 2 (DM2), por su elevada prevalencia, número de discapacidades y alto coste económico, constituye una de las enfermedades crónicas con mayor impacto para el individuo, los sistemas sanitarios y la sociedad. El abordaje multifactorial y el manejo de la hiperglucemia corresponden, fundamentalmente, al ámbito de la atención primaria. Sara Artola Menéndez Médico de familia. Centro de Salud…
Artículo Diamond Study Group
Está disponible para descarga el artículo Effect of Continuous Glucose Monitoring on Glycemic Control in Adults with Type 1 Diabetes Using Insulin Injections. Autores: RoyW. Beck, MD, PhD; Tonya Riddlesworth, PhD; Katrina Ruedy, MSPH; Andrew Ahmann, MD; Richard Bergenstal, MD; Stacie Haller, RD, LD, CDE; Craig Kollman, PhD; Davida Kruger, MSN, APN-BC; Janet B….
Standards or Medical Care in Diabetes 2017
Consulta aquí el artículo Standards or Medical Care in Diabetes 2017, publicado por la American Diabetes Association
Guidelines Osteoporosis
Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update from the American College of Physicians Descarga aquí el artículo
Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM–INSULIN trial
Consulta aquí el artículo: Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM–INSULIN trial